INTRODUCTION
G protein-coupled receptors (GPCRs) represent the largest superfamily of cell surface receptors. Heterotrimeric ligand/GPCR/G protein complexes engender enormous diversity within cell signaling and as such, a large proportion of current pharmaceuticals target GPCRs (Overington et al., 2006) . The majority of these drugs mediate their action through the primary, endogenous ligand binding site, which for GPCRs is known as the orthosteric binding site. However, GPCRs also contain allosteric binding sites; that is, any receptor binding site that is topographically distinct from the orthosteric site (May et al., 2007b) .
GPCR signaling, even at the simplest level, is governed by allosteric interactions with intracellular signaling proteins. Agonist binding within the extracellular domain promotes stabilization of GPCR conformations that preferentially interact with intracellular signaling proteins (Kenakin, 2002) . GPCRs can also interact with transmembrane proteins and allosteric small molecules. These interactions stabilize an alternative subset of receptor conformations which in turn can cause a change in the rate of orthosteric ligand association and/or dissociation (May et al., 2007b) . As a result, a wealth of information with respect to the conformational changes occurring within the receptor binding site can be obtained through assessing ligand binding kinetics under different conditions. However, the rapid nature of agonist kinetics at non-peptide GPCRs in the presence of the active G protein cycle has largely prevented any direct investigation of the binding kinetics of these agonists in living cells.
Over recent years, drug design targeted towards allosteric binding sites on GPCRs has gained momentum within drug discovery. This approach has a number of potential advantages, including the selective manipulation of GPCRs that contain high sequence homology within the orthosteric domain across receptor subtypes and the ability to maintain 5 the spatial and temporal signaling profile of the endogenous ligand; only enhancing or inhibiting receptor activity where and when the endogenous agonist is present (Birdsall et al., 1996) . A fundamental method to detect GPCR allosterism has been to observe a change in the dissociation kinetics of an orthosteric ligand in the presence of a putative allosteric modulator (Christopoulos and Kenakin, 2002) . The mechanism of action for the first identified GPCR allosteric enhancers, a series of adenosine A 1 receptor (A 1 AR) selective 2-amino-3-benzoylthiophene derivatives including PD81,723, was confirmed through detecting a decrease in the rate of agonist dissociation (Bruns and Fergus, 1990) . This method was used more recently to identify adenosine A 3 receptor (A 3 AR) allosteric modulators, including VUF5455 (Gao et al., 2001 ).
To date, the majority of dissociation kinetic assays involve membrane-based radioligand binding, which has a number of limitations. For example, radioligand dissociation is generally measured in the presence of a saturating concentration of competitive orthosteric ligand (Avlani et al., 2004; Bruns and Fergus, 1990; Christopoulos et al., 1997; Dowling and Charlton, 2006; Ellis et al., 1991; Gao et al., 2001; Lazareno and Birdsall, 1995; Lee and el-Fakahany, 1991; May et al., 2007a; Springael et al., 2006) . This requires the assumption that the second ligand does not alter radioligand dissociation. While consistent within a theoretical framework describing competitive interactions between compounds at a monomeric receptor, more complex interactions resulting from multistep ligand binding (Ilien et al., 2009; Swaminath et al., 2004) or receptor dimerization (Christopoulos and Kenakin, 2002; Han et al., 2009; Springael et al., 2006) could lead to a change in the radioligand dissociation rate. In addition, the absence of the G protein cycle in membrane-based assays generates a large bias for an agonist radioligand to detect the active, G protein-coupled, receptor conformation. Finally, membrane-based radioligand binding This study focused on visualizing and quantifying, at the single cell level, the binding kinetics of an adenosine receptor agonist in the absence and presence of allosteric modulators and has used a closed perfusion system maintained under constant pressure and environmentally controlled. An advantage of this technique is that rapid removal of free ligand upon reservoir exchange allows agonist dissociation to be performed in the absence of a saturating concentration of competitive orthosteric ligand. Specifically this study has directly quantified, at the single cell level, the kinetics of the fluorescent adenosine derivative, ABA-X-BY630 (Middleton et al., 2007) , at the human A 1 AR and A 3 AR. Furthermore, the influence of the allosteric modulators, PD81,723 and VUF5455, on the kinetics of ABA-X-BY630 binding and function has been investigated at the human A 1 AR and A 3 AR in live cells.
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8 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 2 mM sodium pyruvate, 1.3 mM CaCl 2 ) containing 0.1% BSA, 2.5 mM probenecid, 0.5 mM Brilliant Black BN, 2.3 μM Fluo-4AM and 0.023% pluronic acid at 37°C for 1 hour. Plates were then loaded onto a fluidics plate reader (FlexStation, Molecular Devices, Sunnyvale, CA, USA) and fluorescence measured (excitation = 485 nm, emission = 520 nm) every 1.52 seconds for up to 200 seconds with the addition of HBSS in the absence or presence of ABA-X-BY630 at 15 seconds.
ERK1/2 Phosphorylation Assay
ERK1/2 phosphorylation was measured using the ERK Surefire TM kit (PerkinElmer).
CHO-A 1 and CHO-A 3 cells seeded into 96-well clear plates were washed twice with PBS and maintained in 100 μL DMEM-F12 containing 2 mM glutamine (DMEM-F12/glutamine) for at least 4 hours before assaying. Cells were then exposed to ABA-X-BY630 for 5 minutes, after which stimulation was terminated by the removal of media and the addition of 40 μL of SureFire TM lysis buffer to each well. A 1:80:20:120 v/v dilution of AlphaScreen TM beads:lysate:activation buffer:reaction buffer in an 5.5 μL total volume was then transferred to a white opaque 384-well Proxiplate TM in the dark. This plate was then incubated in the dark at 37°C for 2 hours after which time the fluorescence signal was measured by an Envision plate reader (PerkinElmer) using standard AlphaScreen TM settings.
Confocal Microscopy
Live cell imaging of non-transfected CHO-K1 (CHO-NT), CHO-A 1 and CHO-A 3 cells seeded onto 32 mm circular coverslips was performed using a Zeiss LSM 510 laser scanning confocal microscope and a Zeiss Plan-Neofluar 40 x 1.3 NA oil-immersion objective. A 633 nm HeNe laser was used for the excitation of ABA-X-BY630 (a BODIPY630/650 conjugate) with emission being detected using a 650nm long-pass filter. A This article has not been copyedited and formatted. The final version may differ from this version. Initial live cell kinetic experiments, characterizing the association and dissociation kinetics of ABA-X-BY630 (3 -100 nM), involved 30 seconds of HBSS perfusion to obtain the basal fluorescence followed by 4 minutes exposure of cells to ABA-X-BY630 after which ABA-X-BY630 perfusion was terminated and replaced by HBSS-only perfusion. In each case, the temperature was maintained at 37C, the flow rate was equal to, or greater than 5 mL/min and the pinhole diameter (1 Airy Unit; 1.1 m optical slice), laser power and gain were kept constant within experiments using the same receptor subtype.
Characterizing the influence of the allosteric modulators, PD81,723 and VUF5455, on ABA-X-BY630 dissociation from the A 1 AR and A 3 AR respectively.
CHO-A 1 and CHO-A 3 cells were exposed to 30 nM ABA-X-BY630 alone for two minutes, after which CHO-A 1 cells only were exposed to 30 nM ABA-X-BY630 in the absence and presence of 10 M PD81,723 for an additional minute. Subsequent to association, ABA-X-BY630 dissociation from A 1 ARs and A 3 ARs was assessed by the This article has not been copyedited and formatted. The final version may differ from this version. During the experiment, cells were pretreated for 1 minute with HBSS in the presence or absence of allosteric modulator, PD81,723 (1 M, 10 M) or VUF5455 (0.1 M, 1 M), after which they were exposed to 30 nM ABA-X-BY630 in the presence of the pretreatment condition for an additional minute. ABA-X-BY630 dissociation was then initiated by perfusion of the pretreatment condition alone. A 488nm argon laser was used for the excitation of Fluo-4 with emission being detected using a 505-550nm band-pass filter. The configuration of the Zeiss 510 laser scanning confocal microscope was kept constant between experiments. As above, ABA-X-BY630 binding was assessed by drawing a region of interest around the plasma membrane of 10 cells within each field of view. In contrast, given the oscillatory and non-synchronous calcium response, the complete field of view was used to
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Data Analysis
All data were fitted using Prism 5 (GraphPad Software, San Diego, CA).
Concentration-response curves for ABA-X-BY630 were fitted to the following equation:
where E MAX is the maximal response and the EC 50 is the molar concentration of ABA-X-BY630 required to generate 50% of E MAX . Association kinetic data were fit to the following mono-exponential association function: 
RESULTS

The nature of the fluid exchange within the perfusion system
This study has used a closed perfusion system, consisting of an imaging cell coupled to six reservoirs (Figure 1a ), in conjunction with a Zeiss LSM 510 laser scanning confocal microscope to directly visualize and quantify fluorescent ligand association and dissociation kinetics at the single cell level. The perfusion system was environmentally controlled, maintained at the physiological temperature of 37C, and kept at constant pressure, promoting laminar flow and preventing loss of focus. Another important aspect of this system is the use of 'infinite dilution' to assess agonist dissociation kinetics (Christopoulos et al., 1997; Lee and el-Fakahany, 1991) . The method of 'infinite dilution' requires dissociated fluorescent ligand to be rapidly removed such that the level of ligand re-association is To further confirm the lack of ligand re-association during the dissociation phase, the binding kinetics of the fluorescent adenosine derivative, ABA-X-BY630, at CHO-A 3 cells were investigated at differing flow rates. The association and dissociation rates of 100 nM ABA-X-BY630 at the A 3 AR were similar at flow rates of 3 -5 mL/min, 6 -10 mL/min, 11 -15 mL/min or 16 -20 mL/min, which reflect 7.5 -12.5, 15 -25, 27.5 -37.5 or 40 -50 complete fluid exchanges within the imaging cell per minute ( Figure 1c ). As such, association appears to be initiated by the exposure of cells to the desired concentration of free ligand, which in turn can be rapidly removed upon the initiation of dissociation. Taken together, these results suggest that the fluid exchange within the perfusion system involves a sharp change in the concentration gradient of free ligand upon reservoir changeover and as such the method of 'infinite dilution' can be used to assess fluorescent ligand dissociation.
All subsequent experiments use a flow rate equal to or greater than 5 mL/min.
Investigating the functional activity of ABA-X-BY630 at the A 1 AR and A 3 AR
The agonist activity of the adenosine derivative, ABA-X-BY630, at the A 1 AR and/or of ABA-X-BY630 at mediating intracellular calcium mobilization and ERK1/2 phosphorylation was 6.1  0.1 and 7.7  0.2 respectively at the A 1 AR and 5.9  0.2 and 7.3  0.2 respectively at the A 3 AR.
Characterization of agonist kinetics at the A 1 AR and A 3 AR
Association and dissociation kinetics of ABA-X-BY630 were assessed at both the fluorescence intensity of non-specific binding was considerably lower than that observed for the corresponding concentration of ABA-X-BY630 in CHO-A 1 and CHO-A 3 cells.
Furthermore for both sets of confocal configurations, membrane localized non-specific binding could only be accurately quantified at 30 and 100 nM ABA-X-BY630 (Figure 2d and 3d). The observed association and dissociation of non-specific binding was rapid, suggesting ABA-X-BY630 has very low affinity for, and therefore was unlikely to become sequestered within, the plasma membrane. The observed association rate (k onobs ) and dissociation kinetics (k off ) for corresponding ABA-X-BY630 concentrations using the CHO-A 1 and CHO-A 3
configurations did not cause a significant difference (unpaired t test) in the non-specific binding kinetics and as such are represented as a combined value (Table 1 ). In addition, no significant difference (unpaired t test) was observed between the dissociation rate of 30 and 100 nM from CHO-NT cells. and 100 nM ABA-X-BY630. In each case, the proportion and rate of the rapidly dissociating component was similar to that expected for, and therefore was assumed to represent, nonspecific binding. As such, the fast component of the biphasic decay was constrained to equal the average dissociation rate estimated for non-specific binding (k off(fast) = 3.81 min -1 ). At both A 1 ARs and A 3 ARs, one-way ANOVA analysis suggested that there was a significant
This article has not been copyedited and formatted. The final version may differ from this version. difference between the k onobs , but not the k off estimates for the different concentrations of ABA-X-BY630 (Table 1) . The observed association rate (k onobs ) and the slow component of the biphasic decay (k off(slow) ) were used to estimate the association rate (k on ) of ABA-X-BY630 at the A 1 AR and A 3 AR (Equation 5). Subsequently, the association (k on ) and dissociation (k off ) rates were used to estimate the affinity of ABA-X-BY630 at both receptors (Equation 6 ). Analysis of these data according to one-way ANOVA suggested that there was no significant difference between the association rate constants (k on ) or equilibrium dissociation constants (pK D ) calculated for the different concentrations of ABA-X-BY630 (Table 1) .
Single cell analysis of agonist binding parameters
Single cell analysis of agonist binding kinetics was performed for 3, 10, 30 and 100 nM ABA-X-BY630 at A 3 ARs ( Figure 4) . As for the grouped analysis, ABA-X-BY630 kinetics were analyzed according to a monoexponential association followed by a monophasic decay for 3 and 10 nM and a biphasic decay with k off(fast) constrained to equal 3.81 min -1 for 30 and 100 nM. Similar to the grouped analysis, results of the single cell analysis suggested that the dominant influence of fluorescent ligand concentration was on the k onobs with a coefficient of determination (r 2 ) for a linear trend of 0.488. When compared to k onobs , there was less correlation between ligand concentration and the estimated k off(slow) , k on and pK D from the single cell analysis which had r 2 values of 0.13, 0.12 and 0.01 respectively.
Investigating the influence of allosteric modulators on agonist dissociation kinetics in whole cells
Ligands competing for the same site on a monomeric receptor should not influence the dissociation kinetics of one another (Figure 5a ). This is clearly shown in Figure 5b where This article has not been copyedited and formatted. The final version may differ from this version. the addition of the competitive ligand, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 100 nM), during the dissociation phase does not influence the dissociation of ABA-X-BY630 (100 nM).
In contrast, if ligands bind simultaneously to two interacting sites, such as in the case of allosterism, cooperative interactions can alter ligand dissociation kinetics (Christopoulos and Kenakin, 2002; May et al., 2007b) . To date, the majority of studies investigating the influence of allosteric modulators on GPCRs use a saturating concentration of unlabelled orthosteric ligand in the absence or presence of allosteric modulator to bind any unoccupied orthosteric binding sites and as such inhibit the re-association of dissociated labeled orthosteric ligand (Christopoulos et al., 1997; Lee and el-Fakahany, 1991) . In contrast, this system has used the method of 'infinite dilution' to assess the dissociation rate of the fluorescent agonist in the absence and presence of allosteric modulator. This method eliminates a number of the issues that can arise when using additional orthosteric ligands and also allows agonist kinetics to be assessed within whole cells can also be observed at the single cell level (Figure 5f ).
Investigating the influence of allosteric modulators on the kinetics of ABA-X-BY630 binding and function
This article has not been copyedited and formatted. The final version may differ from this version. This in turn resulted in a significant increase in the apparent affinity of ABA-X-BY630 for the A 1 AR in the presence of 10 M PD81,723 ( Table 2 ). The significant decrease in the rate of 30 nM ABA-X-BY630 dissociation (k off ) in the presence of 10 M PD81,723 can be clearly observed when the data was normalized (Figure 6d ). In contrast, there is no significant difference between the observed rate of association (k onobs ) for ABA-X-BY630 at the A 1 AR in the absence and presence of 1 M or 10 M PD81,723 (Figure 6c ). This could result from the opposing effects an increased association rate (k on ) and a decreased dissociation rate (k off ) has on the observed rate of association (k onobs ). At the A 1 AR, 1 M VUF5455 mediated a significant decrease in the dissociation rate (k off ) of 30 nM ABA-X-BY630, suggesting that VUF5455 has an allosteric mechanism of action at the A 1 AR ( Figure   6h ; Table 2 ). However, despite decreasing the dissociation rate, a concurrent decrease in the association rate constant (k on ) in the presence of 1 M VUF5455 caused a decrease in the level of 30 nM ABA-X-BY630 specific binding at the A 1 AR (Table 2; Figure 6e ). There was no significant difference between the observed association rate (k onobs ) of 30 nM ABA-X-BY630 at the A 1 AR in the absence or presence of 0.1 M or 1 M VUF5455 (Figure 6g ).
This article has not been copyedited and formatted. The final version may differ from this version. At the A 3 AR, PD81,723 mediated a concentration-dependent decrease in the binding of 30 nM ABA-X-BY630, an increase in the dissociation rate (k off ) and a decrease in the association rate (k on ) of 30 nM ABA-X-BY630 ( Figure 7a ; Table 2 ). The combined changes in ABA-X-BY630 kinetics resulted in a concentration-dependent decrease in the apparent affinity of ABA-X-BY630 for the A 3 AR in the presence of PD81,723 (Table 2) Imaging also allows discrimination between plasma membrane and intracellular ligand
binding. An additional advantage of this method is that it is readily amenable to the study of endogenously expressed receptors in intact primary cells.
The average pK D of ABA-X-BY630, at the A 1 AR and A 3 AR, was 7.3 and 7.9
respectively. The pK D of adenosine for the high and low affinity states at the A 1 AR has previously been estimated as 7.9 and 5.1 respectively (Cohen et al., 1996a) . As such it appears the low concentrations of ABA-X-BY630 used within this study predominantly This article has not been copyedited and formatted. The final version may differ from this version. 
